School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg ...

neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). It is the first and only FDA-approved epinephrine nasal ...

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 millionPreliminary cash, cash equivalents and short-term investments ...

In early August, the FDA approved neffy epinephrine nasal spray to treat emergent type 1 allergic reactions in patients who weigh at least 66 pounds. The approval was based on four studies of 175 ...

ARS Pharmaceuticals, Inc. has announced the filing for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy®. This follows ...

announced today that ARS Pharma has filed for approval of neffy ® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom (U.K.), where it will be marketed as EURneffy ®, on behalf of ...

neffy is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise ...

neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). It is the first and only FDA-approved epinephrine nasal spray ...

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.

About neffy® neffy is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as ...